Sign In
Buy JNJ
$231.29
+2.90 (+1.27%)
At Close: Jun 22, 2026
Is Johnson & Johnson Still the Ultimate Safe Dividend Stock to Buy?
01:43pm, Wednesday, 06'th May 2026
Johnson & Johnson is a Dividend King, with 64 consecutive years of increases. The company only spent 61% of its free cash flow in 2025 on dividend payouts.
6 Pharma Dividend Stocks Yielding Up to 6.44% — and They've Survived Every Market Crash
10:32am, Wednesday, 06'th May 2026
Dividend income arrives whether markets rally or sell off. For investors seeking recurring cash flow, high-yield equities remain the cleanest source outside a paycheck.
These 3 Dividend Stocks Have Raised Their Payouts for a Combined 187 Years. Here's Why That Matters To Passive Income Lovers
09:50am, Wednesday, 06'th May 2026
Earned income disappears the moment you stop working. Dividend income keeps arriving every quarter.
27% of Americans Own ETFs but Allocate Just 6%, Here’s Why That Costs Them Retirement Income
01:45pm, Tuesday, 05'th May 2026
The Charles Schwab Modern Wealth Survey 2025 found that 27% of American investors own ETFs, yet those funds account for only 6% of the average portfolio. Individual stocks: 25%; mutual funds: 13%; cry
Put $5,000 Into This Dividend Giant and Earn Passive Income Every Quarter
10:50am, Tuesday, 05'th May 2026
Passive income is the cash flow that arrives whether you are working, sleeping, or watching the market churn.
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
10:01am, Tuesday, 05'th May 2026
Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.
CVS to drop J&J's Stelara from its main formularies
09:15am, Tuesday, 05'th May 2026
CVS Health said on Tuesday it would prefer lower-cost, interchangeable biosimilars over Johnson & Johnson's psoriasis drug Stelara in its most common drug lists starting July 1.
JNJ-4804 demonstrated highest rates of clinical and endoscopic outcomes compared to golimumab and guselkumab in patients with ulcerative colitis or Crohn's disease who have had inadequate response to
TREMFYA ® demonstrated significantly higher rates of combined fistula remission – complete external closure of draining fistulas and absence of fluid collection on MRI – compared to placebo at We
Johnson & Johnson Announces Pivotal Clinical Study Results for a New Soft-Tissue Surgical Robotic System
07:00am, Tuesday, 05'th May 2026
SANTA CLARA, Calif.--(BUSINESS WIRE)--Johnson & Johnson announces results from the first clinical study of the investigational OTTAVA™ Robotic Surgical System.
ABBV Stock Up 5% on Robust Q1 Performance: Time to Buy, Sell or Hold?
02:56pm, Monday, 04'th May 2026
AbbVie ABBV stock has risen around 5% since it announced robust first-quarter 2026 results on April 29. It beat estimates for both earnings and sales and the guidance for 2026 revenues and earnings w
A $2 Million Portfolio Still Has a Safety Trap Most Investors Over 60 Miss
10:29am, Monday, 04'th May 2026
You retired with about $2 million saved. The mortgage is gone, Social Security covers the basics, and the brokerage statement looks healthy enough that you finally stopped checking it daily. Somewhere
Which Is the Better Dividend ETF, iShares' HDV or Vanguard's VYM?
09:55am, Monday, 04'th May 2026
Expense ratios, sector exposures, and risk profiles set these high-yield ETFs apart. See how their strategies align with different investor priorities.
CAPLYTA ® ranked highest among FDA-approved adjunctive therapies across four measures of efficacy, based on indirect comparisons from placebo plus antidepressant therapy-controlled trials Among the s
The Best Dividend Stocks to Buy and Hold Forever
04:44am, Monday, 04'th May 2026
Coca-Cola is a "forever" stock for Warren Buffett and a Dividend King. Johnson & Johnson has proven its ability to survive and thrive over the long term.
